Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Normal Volunteers Given Punch Skin Biopsies

NCT00916292 is registered in ClinicalTrials.gov with Phage Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00916292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00916292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Normal Volunteers Given Punch Skin Biopsies
Lead sponsor
Phage Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2012
Completion date
September 30, 2013
Enrollment
8 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic foot ulcers